News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Fosun Pharma Terminates $531 Million Out-licensing Deal With Sellas


7/2/2014 9:01:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In a shocking announcement, Fosun Pharma declared it was ending its $531 million out-licensing deal with Sellas Clinicals Holding, a Greek-Swiss pharma. The transaction gave Sellas ex-China rights to two major Fosun-developed drug programs, one for cancer, the other diabetes. According to the terms of the deal, Fosun was due $11 million in an upfront payment. To date, Sellas has paid only $2 million, even though the transaction was signed in October of 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today
Read at Reuters


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES